A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Conditions: LGLL – Large Granular Lymphocytic Leukemia; Primary Cutaneous T-Cell Lymphoma – Category; Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma; Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma; Hepatosplenic T-cell Lymphoma; Subcutaneous Panniculitis-Like T-Cell Lymphoma; Aggressive NK Cell Leukemia; Systemic EBV1 T-cell Lymphoma, if CD8 Positive; Hydroa Vacciniforme-Like Lymphoproliferative Disorder; Extranodal NK/T Cell Lymphoma, Nasal Type; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma; Indolent Chronic Lymphoproliferative Disorder (CLPD) (CD8+ or NK Derived) of the GI Tract; Other CD8+/NK Cell Driven Lymphoma Not Listed Above
Intervention: Drug: DR-01
Sponsors: Dren Bio; ProTrials Research Inc.; Novotech
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.